Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy in a pill) at ObesityWeek 2025, including demonstrated reductions in cardiovascular risk factors
Christopher McGowan, a North Carolina physician who is triple board certified in internal medicine, gastroenterology and obesity medicine, calls microdosing programs murky and a complete Wild West. Dr
L.RupprechtL
A good example are Genome-wide association studies (GWAS), where researchers search the whole genome for any association (between single nucleotide polymorphisms, or SNPs) and an outcome of interest (height, depression, high cholesterol, cancer, etc)
The medication was generally well tolerated, with a side effect profile consistent with other GLP-1 receptor agonists.